Genine Winslow
Company: Chameleon Bioscience
Job title: Chief Scientific Officer
Seminars:
PANEL Q&A: An Overview & Assessment of Current & Future Strategies to Circumvent or Lessen the Innate & Early Adaptive Immune Response to Gene Therapy 12:30 pm
day: Re-Dosing Discussion Day
Immune Evasive AAV for Repeat Dosing 12:00 pm
Current AAV technology advantages and disadvantages Data showing Chameleon’s EVADER technology repeat dosing in mice Next steps: EVADER developmentRead more
day: Re-Dosing Discussion Day